



Billing Code 4410-09-M

DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
MANUFACTURER OF CONTROLLED SUBSTANCES
NOTICE OF REGISTRATION
NEKTAR THERAPEUTICS

By Notice dated July 17, 2012, and published in the Federal Register on July 26, 2012, 77 FR 43862, Nektar Therapeutics, 1112 Church Street, Huntsville, Alabama 35801, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Fentanyl (9801), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the listed controlled substance in support of product development.

No comments or objections have been received. DEA has considered the factors in 21 USC § 823(a) and determined that the registration of Nektar Therapeutics to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Nektar Therapeutics to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and

testing of the company's physical security systems;
verification of the company's compliance with state and
local laws; and review of the company's background and
history. Therefore, pursuant to 21 USC § 823(a), and in
accordance with 21 CFR § 1301.33, the above named company
is granted registration as a bulk manufacturer of the basic
class of controlled substance listed.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: November 5, 2012

[FR Doc. 2012-27567 Filed 11/09/2012 at 8:45 am; Publication Date: 11/13/2012]